Reflects potential milestone payments to be received upon achievement of pre-specified milestone.

No definition available.

Name:	tgtx_AdditionalAmountReceivableOnAchievementOfPreSpecifiedMilestones
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	tgtx_LicenseAgreementLineItems
Namespace Prefix:	tgtx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum potential milestone payments upon the achievement of specific clinical regulatory and commercial milestone events.

+ References

No definition available.

+ Details

Name:	tgtx_MaximumPotentialPaymentsPayable
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the maximum sales for royalty expense.

+ References

No definition available.

+ Details

Name:	tgtx_MaximumSalesForRoyaltyExpense
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

It represents non cash research and development expense

+ References

No definition available.

+ Details

Name:	tgtx_NonCashResearchAndDevelopmentExpense
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The aggregate expense related to the issuance of stock in connection with in-licensing agreements during the reporting period.

+ References

No definition available.

+ Details

Name:	tgtx_NonCashStockExpense
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the Royalty payment Effective Percentage.

+ References

No definition available.

+ Details

Name:	tgtx_RoyaltyPaymentEffectivePercentage
Namespace Prefix:	tgtx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Represents the value eligible to receive regulatory filing, approval and sales based milestones during the period.

+ References

No definition available.

+ Details

Name:	tgtx_SaleBasedMileStonePayment
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents amount received for sub license.

+ References

No definition available.

+ Details

Name:	tgtx_UpfrontFeeReceivedFromSubLicense
Namespace Prefix:	tgtx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

+ Details

Name:	us-gaap_IncomeTaxExpenseBenefit
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicensesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 730

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The cash outflow associated with the investment in or advances to an entity in which the reporting entity shares control of the entity with another party or group.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585

+ Details

Name:	us-gaap_PaymentsToAcquireInterestInJointVenture
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Cash received for fees during the current period. This element excludes cash proceeds from license fees.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585

+ Details

Name:	us-gaap_ProceedsFromFeesReceived
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

+ Details

Name:	us-gaap_SharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.

+ References

No definition available.

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=tgtx_CollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tgtx_LigandMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tgtx_OpusPointPartnersLlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=tgtx_RhizenMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

LICENSE AGREEMENTS (Details Textual) (USD $)	12 Months Ended			1 Months Ended
LICENSE AGREEMENTS (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Jun. 23, 2014
License Agreement [Line Items]
License revenue	$ 152,381us-gaap_LicensesRevenue	$ 152,381us-gaap_LicensesRevenue
Deferred Revenue	1,676,000us-gaap_DeferredRevenue	1,829,000us-gaap_DeferredRevenue
Additional Amount Receivable On Achievement Of Pre Specified Milestones	5,000,000
Income taxes	0us-gaap_IncomeTaxExpenseBenefit	0us-gaap_IncomeTaxExpenseBenefit
Non Cash Stock Expense	5,350,094tgtx_NonCashStockExpense	0tgtx_NonCashStockExpense
Other Research and Development Expense	26,004,687	12,621,161
Licensing Agreements [Member]
License Agreement [Line Items]
Income taxes			330,000
Proceeds from Fees Received			2,000,000
Ligand [Member]
License Agreement [Line Items]
Stock Issued During Period, Shares, Issued for Services				125,000
Maximum Potential Payments Payable				207,000,000
Ligand [Member] \| Maximum [Member]
License Agreement [Line Items]
Royalty payment Effective Percentage				9.50%
Maximum sales for royalty expense				1,000,000,000
Ligand [Member] \| Minimum [Member]
License Agreement [Line Items]
Royalty payment Effective Percentage				6.00%
Opus Point Partners, Llc [Member]
License Agreement [Line Items]
Royalty payment Effective Percentage				1.00%
Opus Point Partners, Llc [Member] \| Maximum [Member]
License Agreement [Line Items]
Maximum sales for royalty expense				1,000,000,000
Rhizen [Member]
License Agreement [Line Items]
Payments to Acquire Interest in Joint Venture	4,000,000
Shares, Issued	371,530
Future Potential Milestone Based Payments	175,000,000
Other Research and Development Expense	4,000,000
Research and Development Expense [Member] \| Ligand [Member]
License Agreement [Line Items]
Non Cash Stock Expense	1,211,250
Research and Development Expense [Member] \| Rhizen [Member]
License Agreement [Line Items]
Non Cash Research And Development Expense	4,100,000
Collaboration Agreement [Member]
License Agreement [Line Items]
Upfront Fee Received From Sub License		$ 2,000,000